MX2017016519A - Biomarcadores para composiciones de nanoparticulas. - Google Patents
Biomarcadores para composiciones de nanoparticulas.Info
- Publication number
- MX2017016519A MX2017016519A MX2017016519A MX2017016519A MX2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A
- Authority
- MX
- Mexico
- Prior art keywords
- biomarkers
- nanoparticle compositions
- compositions
- mtor
- limo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186309P | 2015-06-29 | 2015-06-29 | |
| PCT/US2016/040196 WO2017004264A1 (en) | 2015-06-29 | 2016-06-29 | Biomarkers for nanoparticle compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016519A true MX2017016519A (es) | 2018-08-16 |
Family
ID=57609078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016519A MX2017016519A (es) | 2015-06-29 | 2016-06-29 | Biomarcadores para composiciones de nanoparticulas. |
| MX2023013010A MX2023013010A (es) | 2015-06-29 | 2017-12-15 | Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013010A MX2023013010A (es) | 2015-06-29 | 2017-12-15 | Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20180177771A1 (enExample) |
| EP (1) | EP3313381A4 (enExample) |
| JP (4) | JP2018527308A (enExample) |
| KR (2) | KR20240144442A (enExample) |
| AU (3) | AU2016285727B9 (enExample) |
| CA (1) | CA2990703C (enExample) |
| HK (1) | HK1254398A1 (enExample) |
| IL (2) | IL256326B2 (enExample) |
| MX (2) | MX2017016519A (enExample) |
| WO (1) | WO2017004264A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675578B2 (en) | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| WO2019140257A1 (en) * | 2018-01-11 | 2019-07-18 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for characterizing and treating prostate cancer |
| AU2019239953B2 (en) * | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| KR20210024471A (ko) * | 2018-05-22 | 2021-03-05 | 아브락시스 바이오사이언스, 엘엘씨 | 폐고혈압을 치료하기 위한 방법 및 조성물 |
| CN111187834B (zh) * | 2019-01-08 | 2021-01-22 | 中国科学院上海营养与健康研究所 | 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用 |
| MX2021011230A (es) * | 2019-03-19 | 2022-03-11 | Abraxis Bioscience Llc | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
| CN114945358A (zh) * | 2019-11-11 | 2022-08-26 | 阿布拉科斯生物科学有限公司 | 用于纳米颗粒组合物的生物标记 |
| AU2021358768A1 (en) * | 2020-10-06 | 2023-05-18 | The Regents Of The University Of Colorado, A Body Corporate | Subject-specific treatments for venetoclax-resistant acute myeloid leukemia |
| WO2022186673A1 (ko) * | 2021-03-05 | 2022-09-09 | 전남대학교산학협력단 | 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘 |
| WO2024215799A1 (en) * | 2023-04-11 | 2024-10-17 | Leapfrog Bio, Inc. | Pi3k inhibitors for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3417859A1 (en) * | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CN103221042B (zh) * | 2010-06-02 | 2016-02-10 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
| EP3225697A3 (en) * | 2010-12-30 | 2017-11-22 | Foundation Medicine, Inc. | Optimization of multigene analysis of tumor samples |
| JP6309610B2 (ja) * | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| WO2014144451A2 (en) * | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to rapamycin analogs |
| JP2018521058A (ja) * | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
-
2016
- 2016-06-29 US US15/738,090 patent/US20180177771A1/en not_active Abandoned
- 2016-06-29 KR KR1020247031052A patent/KR20240144442A/ko not_active Ceased
- 2016-06-29 AU AU2016285727A patent/AU2016285727B9/en active Active
- 2016-06-29 KR KR1020187002292A patent/KR102708679B1/ko active Active
- 2016-06-29 IL IL256326A patent/IL256326B2/en unknown
- 2016-06-29 IL IL312318A patent/IL312318A/en unknown
- 2016-06-29 EP EP16818726.8A patent/EP3313381A4/en not_active Withdrawn
- 2016-06-29 MX MX2017016519A patent/MX2017016519A/es unknown
- 2016-06-29 CA CA2990703A patent/CA2990703C/en active Active
- 2016-06-29 HK HK18113475.7A patent/HK1254398A1/zh unknown
- 2016-06-29 JP JP2017568138A patent/JP2018527308A/ja active Pending
- 2016-06-29 WO PCT/US2016/040196 patent/WO2017004264A1/en not_active Ceased
-
2017
- 2017-12-15 MX MX2023013010A patent/MX2023013010A/es unknown
-
2021
- 2021-06-25 JP JP2021105535A patent/JP2021169457A/ja active Pending
- 2021-12-20 AU AU2021290200A patent/AU2021290200B2/en active Active
-
2022
- 2022-08-11 US US17/886,329 patent/US20230080409A1/en not_active Abandoned
-
2023
- 2023-02-01 JP JP2023013778A patent/JP2023071656A/ja active Pending
-
2024
- 2024-07-05 AU AU2024204661A patent/AU2024204661A1/en active Pending
-
2025
- 2025-01-15 US US19/022,821 patent/US20250152563A1/en active Pending
- 2025-02-21 JP JP2025026646A patent/JP2025097987A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016285727A1 (en) | 2018-02-01 |
| EP3313381A4 (en) | 2019-02-27 |
| IL256326B2 (en) | 2024-09-01 |
| JP2021169457A (ja) | 2021-10-28 |
| US20180177771A1 (en) | 2018-06-28 |
| AU2021290200B2 (en) | 2024-05-02 |
| WO2017004264A1 (en) | 2017-01-05 |
| CA2990703C (en) | 2024-04-30 |
| IL256326A (en) | 2018-02-28 |
| KR20240144442A (ko) | 2024-10-02 |
| US20250152563A1 (en) | 2025-05-15 |
| AU2016285727B2 (en) | 2021-09-23 |
| AU2016285727B9 (en) | 2021-09-30 |
| US20230080409A1 (en) | 2023-03-16 |
| KR102708679B1 (ko) | 2024-09-24 |
| JP2025097987A (ja) | 2025-07-01 |
| JP2018527308A (ja) | 2018-09-20 |
| IL256326B1 (en) | 2024-05-01 |
| IL312318A (en) | 2024-06-01 |
| AU2024204661A1 (en) | 2024-07-25 |
| HK1254398A1 (zh) | 2019-07-19 |
| JP2023071656A (ja) | 2023-05-23 |
| KR20180019230A (ko) | 2018-02-23 |
| CA2990703A1 (en) | 2017-01-05 |
| AU2021290200A1 (en) | 2022-01-20 |
| EP3313381A1 (en) | 2018-05-02 |
| MX2023013010A (es) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013010A (es) | Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor. | |
| CY1124926T1 (el) | Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| MX2016009135A (es) | Heteroarilos y usos de estos. | |
| MX2015008889A (es) | Metodo para tratar cancer con base en el estado de la mutacion k-ras. | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| MX2019009361A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
| MX2017000546A (es) | Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek. | |
| MX2020001550A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX385315B (es) | Composiciones y metodos para inhibir actividad de arginasa. | |
| MX2015015738A (es) | Derivados del bipirazol como inhibidores de janus cinasa (jak). | |
| MX2021008064A (es) | Antagonista de union al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cancer. | |
| CR20120528A (es) | Métodos para tratar el cáncer | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| AR096478A1 (es) | Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos | |
| MX2017004600A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
| ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| CY1123408T1 (el) | Φαρμακευτικες συνθεσεις και χρηση των αυτων | |
| CR20150148A (es) | Azaindolinas | |
| BR112018068027A2 (pt) | método para tratar câncer em um paciente e composição farmacêutica |